{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T18:55:44Z","timestamp":1770576944316,"version":"3.49.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Chem."],"abstract":"<jats:p>A class of phosphane gold(I) compounds, made of azoles and phosphane ligands, was evaluated for a screening on the regards of Breast Cancer cell panels (BC). The compounds possess N-Au-P or Cl-Au-P bonds around the central metal, and they differ for the presence of aprotic or protic polar groups in the azoles and\/or the phosphane moieties to tune their hydrophilicity. Among the six candidates, only the compounds having the P-Au-N environment and not displaying neither the hydroxyl nor carboxyl groups in the ligands were found active. The compounds were screened by MTT tests in SKBR3, A17, and MDA-MB231 cancer cells, and two compounds (namely the 4,5-dicyano-imidazolate-1yl-gold(I)-(triphenylphosphane, 5, and 4,5-dichloro-imidazolate-1yl-gold(I)-triphenylphosphane, 6) were found very cytotoxic, with the most active with an IC<jats:sub>50<\/jats:sub> value of 3.46 \u03bcM in MDA-MB231 cells. By performing enzymatic assays in the treated cells lysates, the residual enzymatic activity of dihydrofolate reductase (DHFR) has been measured after cell treatment for 4 or 12 h in comparison with control cells. Upon 12 h of treatment, the activity of DHFR was significantly reduced in both SKBR3 and A17 cells by compounds 5 and 6, but not in human MDA-MB231 cells; interestingly, it was found remarkably high after 4 h of treatment, revealing a time dependence for the DHFR enzymatic assays. The DHFR inhibition data have been compared to those for the thioredoxin reductase (TrxR), the most recognized molecular target for gold compounds. For this latter, similar residual activities (i.e., 37 and 49% for the match of SKBR3 cells and compound 5 or 6, respectively) were found. Binding studies on the regards of ct-DNA (calf-thymus-DNA) and of plasma transporters proteins, such as BSA (bovine serum albumin) and ATF (apo transferrin), were performed. As expected for gold compounds, the data support strong binding to proteins (K<jats:sub>sv<\/jats:sub> values range: 1.51 \u00f7 2.46 \u00d7 10<jats:sup>4<\/jats:sup> M<jats:sup>\u22121<\/jats:sup>) and a weaker interaction with ct-DNA's minor groove (K<jats:sub>sv<\/jats:sub> values range: 1.55 \u00f7 6.12 \u00d7 10<jats:sup>3<\/jats:sup> M<jats:sup>\u22121<\/jats:sup>).<\/jats:p>","DOI":"10.3389\/fchem.2020.602845","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T07:29:24Z","timestamp":1610177364000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells"],"prefix":"10.3389","volume":"8","author":[{"given":"Rossana","family":"Galassi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Gambini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Vincenzetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Lupidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augusto","family":"Amici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Marchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junbiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Pucciarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1039\/c1mt00062d","article-title":"Gold compounds as therapeutic agents for human diseases","volume":"3","author":"Berners-Price","year":"2011","journal-title":"Metallomics"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1039\/C3DT52524D","article-title":"A golden future in medicinal inorganic chemistry: the promise of anticancer gold organometallic compounds","volume":"43","author":"Bertrand","year":"2014","journal-title":"Dalton Trans."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.ccr.2009.02.026","article-title":"Thioredoxin reductase: a target for gold compounds acting as potential anticancer drugs","volume":"253","author":"Bindoli","year":"2009","journal-title":"Coord. Chem. Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"R137","DOI":"10.1186\/bcr3342","article-title":"p130Cas\/Cyclooxygenase-2 axis in the control of mesenchymal plasticity of breast cancer cells","volume":"14","author":"Bisaro","year":"2012","journal-title":"Breast Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem"},{"key":"B6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin"},{"key":"B7","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/9780470132579.ch59","article-title":"Synthesis of gold-containing mixed-metal cluster complexes","volume-title":"Inorganic Syntheses","author":"Bruce","year":"2007"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1056\/NEJMp058197","article-title":"The distinctive nature of HER2-positive breast cancers","volume":"353","author":"Burstein","year":"2005","journal-title":"N. Engl. J. Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"9554","DOI":"10.1039\/c1cc10860c","article-title":"Therapeutic applications of gold complexes: lipophilic gold(III) cations and gold(I) complexes for anti-cancer treatment","volume":"47","author":"Che","year":"2011","journal-title":"Chem. Commun."},{"key":"B10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3390\/biom8040175","article-title":"Study of new therapeutic strategies to combat breast cancer using drug combinations","volume":"8","author":"Correia","year":"2018","journal-title":"Biomolecules"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.3892\/or.2020.7818","article-title":"Auranofin inhibits the proliferation of lung cancer cells via necrosis and caspase-dependent apoptosis","volume":"44","author":"Cui","year":"2020","journal-title":"Oncol. Rep"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.4155\/fmc.14.87","article-title":"Gold(III) complexes in medicinal chemistry","volume":"6","author":"da Silva Maia","year":"2014","journal-title":"Future Med. Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.bbagen.2011.07.016","article-title":"Transferrin receptors and the targeted delivery of therapeutic agents against cancer","volume":"1820","author":"Daniels","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1200\/JCO.1990.8.9.1483","article-title":"Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the national surgical adjuvant breast and bowel project B-15","volume":"8","author":"Fisher","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1039\/c2dt11781a","article-title":"Synthesis and characterization of azolate gold(I) phosphane complexes as thioredoxin reductase inhibiting antitumor agents","volume":"41","author":"Galassi","year":"2012","journal-title":"Dalton Trans."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1039\/C4DT01542H","article-title":"A study on the inhibition of dihydrofolate reductase (DHFR) from Escherichia coli by gold(I) phosphane compounds. X-ray crystal structures of (4,5-dichloro-1H-imidazolate-1-yl)-triphenylphosphane-gold(I) and (4,5-dicyano-1H-imidazolate-1-yl)-triphenylphosphane-gold(I)","volume":"44","author":"Galassi","year":"2015","journal-title":"Dalton Trans"},{"key":"B17","doi-asserted-by":"publisher","first-page":"14124","DOI":"10.1021\/ic401948p","article-title":"Solventless supramolecular chemistry via vapor diffusion of volatile small molecules upon a new trinuclear silver(I)-nitrated pyrazolate macrometallocyclic solid: an experimental\/theoretical investigation of the dipole\/quadrupole chemisorption phenomena","volume":"52","author":"Galassi","year":"2013","journal-title":"Inorg. Chem"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1038\/sj.onc.1210920","article-title":"Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice","volume":"27","author":"Gali\u00e8","year":"2008","journal-title":"Oncogene"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1093\/carcin\/bgi158","article-title":"Mammary carcinoma provides highly tumourigenic and invasive reactive stromal cells","volume":"26","author":"Gali\u00e8","year":"2005","journal-title":"Carcinogenesis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ejmech.2018.06.002","article-title":"In vitro and in vivo studies of gold(I) azolate\/phosphane complexes for the treatment of basal like breast cancer","volume":"155","author":"Gambini","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.bbagen.2011.10.013","article-title":"Regulation of iron transport and the role of transferrin","volume":"1820","author":"Gkouvatsos","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"B22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejmech.2016.03.002","article-title":"Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity","volume":"115","author":"Hui-Li","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/(SICI)1097-4644(19971001)67:1<24::AID-JCB3>3.0.CO;2-Y","article-title":"Distinct roles for Sp1 and E2F sites in the growth\/cell cycle regulation of the DHFR promoter","volume":"67","author":"Jensen","year":"1997","journal-title":"J. Cell. Biochem"},{"key":"B24","doi-asserted-by":"publisher","first-page":"12335","DOI":"10.1038\/s41598-019-48584-5","article-title":"Gold(I\/III)-phosphine complexes as potent antiproliferative agents","volume":"9","author":"Kim","year":"2019","journal-title":"Sci. Rep."},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-46312-4","volume-title":"Principles of Fluorescence Spectroscopy, 3rd Edn","author":"Lakowicz","year":"2006"},{"key":"B26","first-page":"2425","article-title":"The thioredoxin-thioredoxin reductase system: over-expression in human cancer","volume":"23","author":"Lincoln","year":"2003","journal-title":"Anticancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jinorgbio.2007.09.003","article-title":"In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake","volume":"102","author":"Liu","year":"2008","journal-title":"J. Inorg. Biochem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e14131","DOI":"10.1371\/journal.pone.0014131","article-title":"Mesenchymal\/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies","volume":"5","author":"Marchini","year":"2010","journal-title":"PLoS ONE"},{"key":"B29","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S0022-2836(61)80047-8","article-title":"A procedure for the isolation of deoxyribonucleic acid from micro-organisms","volume":"3","author":"Marmur","year":"1961","journal-title":"J. Mol. Biol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s002800000166","article-title":"Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes","volume":"46","author":"McKeage","year":"2000","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1021\/ml500231b","article-title":"Protein recognition of gold-based drugs: 3D structure of the complex formed when lysozyme reacts with aubipyc","volume":"5","author":"Messori","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"B32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.molstruc.2006.05.004","article-title":"Stability and structural features of DNA intercalation with ethidium bromide, acridine orange and methylene blue","volume":"827","author":"Nafisi","year":"2007","journal-title":"J. Mol. Struct."},{"key":"B33","first-page":"1609","article-title":"A perspective on anti-EGFR therapies targeting triple-negative breast cancer","volume":"6","author":"Nakai","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/med.20168","article-title":"Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies","volume":"30","author":"Nobili","year":"2010","journal-title":"Med. Res. Rev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1021\/bi00354a038","article-title":"Electron spin resonance and magnetic relaxation studies of gadolinium(III) complexes with human transferrin","volume":"25","author":"O'Hara","year":"1986","journal-title":"Biochemistry"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1021\/bi00279a016","article-title":"Interactions of porphyrins with nucleic acids","volume":"22","author":"Pasternack","year":"1983","journal-title":"Biochemistry"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/hep.20720","article-title":"Albumin: biochemical properties and therapeutic potential","volume":"41","author":"Quinlan","year":"2005","journal-title":"Hepatology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s00775-019-01716-8","article-title":"Synthesis, characterization, DFT study, DNA\/BSA-binding affinity, and cytotoxicity of some dinuclear and trinuclear gold(III) complexes","volume":"24","author":"Radisavljevi\u0107","year":"2019","journal-title":"JBIC J. Biol. Inorg. Chem."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3390\/molecules24061140","article-title":"DHFR inhibitors: reading the past for discovering novel anticancer agents","volume":"24","author":"Raimondi","year":"2019","journal-title":"Molecules"},{"key":"B40","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/ijc.32410","article-title":"Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer","volume":"146","author":"Raninga","year":"2020","journal-title":"Int. J. Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jinorgbio.2010.10.016","article-title":"In vitro antitumor activity of water soluble Cu(I), Ag(I) and Au(I) complexes supported by hydrophilic alkyl phosphine ligands","volume":"105","author":"Santini","year":"2011","journal-title":"J. Inorg. Biochem"},{"key":"B42","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.poly.2009.06.007","article-title":"Comparative studies on the cytotoxicity, cellular and nuclear uptake of a series of chloro gold(I) phosphine complexes","volume":"29","author":"Scheffler","year":"2010","journal-title":"Polyhedron"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s10549-011-1935-y","article-title":"Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival\u2014a retrospective multi-centre cohort study","volume":"132","author":"Schwentner","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"B44","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00280-005-0063-y","article-title":"Characterizations of irofulven cytotoxicity in combination with cisplatinand oxaliplatin in human colon, breast, and ovarian cancer cells","volume":"57","author":"Serova","year":"2006","journal-title":"Cancer Chemother. Pharmacol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","article-title":"Efficacy of neoadjuvant cisplatin in triple-negative breast cancer","volume":"28","author":"Silver","year":"2010","journal-title":"J. Clin. Oncol"},{"key":"B46","first-page":"1423","article-title":"Transferrin directed delivery of adriamycin to human cells","volume":"18","author":"Singh","year":"1998","journal-title":"Anticancer Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1039\/c2pp25162k","article-title":"Probing the adverse temperature dependence in the static fluorescence quenching of BSA induced by a novel anticancer hydrazone","volume":"11","author":"Tong","year":"2012","journal-title":"Photochem. Photobiol. Sci"},{"key":"B48","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.semcancer.2006.09.004","article-title":"On the potential of thioredoxin reductase inhibitors for cancer therapy","volume":"16","author":"Urig","year":"2006","journal-title":"Semin. Canc. Biol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: A review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"B50","first-page":"799","article-title":"Doxorubicin-gallium-transferrin conjugate overcomes multidrug resistance: evidence for drug accumulation in the nucleus of drug resistant MCF-7\/ADR cells","volume":"20","author":"Wang","year":"2000","journal-title":"Anticancer Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"105123","DOI":"10.1016\/j.phrs.2020.105123","article-title":"Acetylshikonin isolated from lithospermum erythrorhizon roots inhibits dihydrofolate reductase and hampers autochthonous mammary carcinogenesis in \u039416HER2 transgenic mice","volume":"161","author":"Wang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1258\/0004563021902152","article-title":"Serum transferrin receptor assays and their application","volume":"39","author":"Worwood","year":"2002","journal-title":"Ann. Clin. Biochem."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e96082","DOI":"10.1371\/journal.pone.0096082","article-title":"Synthesis, characterization, in vitro cytotoxicity, and apoptosis-inducing properties of ruthenium(II) complexes","volume":"9","author":"Xu","year":"2014","journal-title":"PLoS ONE"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.18632\/oncotarget.12284","article-title":"Triple-negative breast cancer: is there a treatment on the horizon?","volume":"8","author":"Yao","year":"2016","journal-title":"Oncotarget"},{"key":"B55","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/nar\/26.2.650","article-title":"Binding of double-stranded DNA by Escherichia coli RecA protein monitored by a fluorescent dye displacement assay","volume":"26","author":"Zaitsev","year":"1998","journal-title":"Nucleic Acids Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"16932","DOI":"10.1038\/s41598-018-35237-2","article-title":"Induction of N-Ras degradation by flunarizine-mediated autophagy","volume":"8","author":"Zheng","year":"2018","journal-title":"Sci. Rep."},{"key":"B57","doi-asserted-by":"publisher","first-page":"8786","DOI":"10.1039\/C5CS00132C","article-title":"Chemical biology of anticancer gold(III) and gold(I) complexes","volume":"44","author":"Zou","year":"2015","journal-title":"Chem. Soc. Rev."}],"container-title":["Frontiers in Chemistry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2020.602845\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T01:02:00Z","timestamp":1610586120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2020.602845\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":57,"alternative-id":["10.3389\/fchem.2020.602845"],"URL":"https:\/\/doi.org\/10.3389\/fchem.2020.602845","relation":{},"ISSN":["2296-2646"],"issn-type":[{"value":"2296-2646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,11]]},"article-number":"602845"}}